Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
NCT05214001 · Messoud Ashina, MD · PHASE4 · terminated · last registry update 2025-05-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Issues with recruitment” | – | Registry record, Messoud Ashina, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR1F within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-11Results posted on the registry: University of California, San Diego, amisulpride + bromocriptine (NCT04128683)
- 2024-10-21Results posted on the registry: Technical University of Munich, Olanzapine or amisulpride (NCT01029769)
- 2024-09-19Results posted on the registry: All India Institute of Medical Sciences, Bhubaneswar, Amisulpride + Olanzapine-Fluoxetine Combination (NCT04876521)
- 2024-09-05Phase 3 first posted: Benaroya Research Institute, Amisulpride IV Prevention + Amisulpride IV Treatment (NCT06585540)
- 2024-06-24Also stopped (withdrawn): University of California, Los Angeles, Amisulpride 50 MG (NCT05956600)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision